Sixth sero survey shows Delhi had seropositivity of 97%: Jain

All districts were found to have a seroprevalence of more than 95 per cent, he said

A health worker takes a swab at a Covid-19 testing site in Uttar Pradesh, on May 4.(Photo: Bloomberg)
Press Trust of India New Delhi
2 min read Last Updated : Oct 28 2021 | 3:27 PM IST

The sixth serological survey showed that the national capital had a seropositivity rate of 97 per cent, Delhi Health Minister Satyendar Jain said on Thursday.

All districts were found to have a seroprevalence of more than 95 per cent, he said.

"Women had a higher seropositivity rate than men. Those aged below 18 had a seropositivity rate of 88 per cent, while those aged above 18 had a seropositivity rate of 97 to 98 per cent," Jain told reporters here.

The people who have been vaccinated had a seropositivity rate of over 97 per cent, while those who have not been inoculated had a seropositivity rate of 90 per cent, he added.

"This was the largest sero survey carried out and 28,000 samples were collected," he said.

This is the first survey to be done after Delhi was hit by a brutal second wave of the Covid pandemic in April and May. The fifth round of sero survey conducted in January had shown that 56.13 per cent of the people in Delhi had developed antibodies against COVID-19.

In April and May, Delhi battled a brutal second wave of the pandemic that claimed a massive number of lives with oxygen shortage and reduced supplies of essential medicines at hospitals adding to the woes.

On April 20, Delhi had reported 28,395 cases, the highest in the city since the beginning of the pandemic. On April 22 the case positivity rate was 36.2 per cent, the highest so far. The highest number of 448 deaths was reported on May 3.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Oct 28 2021 | 3:27 PM IST

Next Story